Kyowa Kirin company profile

4151 · TSE · JPY

Compare Kyowa Kirin
¥2,600.50Change from previous close: +0.60%Absolute change: +¥15.50

Close · November 16, 2026

Company profile

Kyowa Kirin has 5,161 employees and is headquartered in Chiyoda, Japan.

Kyowa Kirin sells pharmaceuticals across Japan, the Americas, Europe and Asia, and in other international markets, and its development pipeline spans several therapeutic areas. Its marketed products include Ziftomenib, an oral menin inhibitor for adult relapsed or refractory acute myeloid leukemia with an NPM1 mutation, and Lumicef for palmoplantar pustulosis. Among its late-stage candidates are rocatinlimab for atopic dermatitis and prurigo nodularis, and infigratinib for achondroplasia, both in Phase III trials, alongside programs in ophthalmology, rare metabolic disorders and oncology. The company has research and development partnerships with AstraZeneca and Amgen, and it is a subsidiary of Kirin Holdings Company, Limited.

In the fiscal year ended December 2025, Kyowa Kirin reported revenue of 496.8 billion yen, up 0.3% from the previous year, and net income of 67.0 billion yen. The company employs 5,161 people and is headquartered in Chiyoda, Japan. It was incorporated in 1949 and adopted its current name in July 2019, when it was previously known as Kyowa Hakko Kirin Co., Ltd.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
Japan
Headquarters
Otemachi Financial City Grand Cube, 100-0004, Chiyoda
Employees
5,161
Chief executive
Abdul Hafeez Mullick
Founded
1949
Fiscal year
January - December
Listing
4151 · TSE
Indices
Nikkei 225
Currency
JPY
ISIN
JP3256000005

Kyowa Kirin and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Kyowa Kirin4151Japan$8.46B5,16121.8%16.6
Eisai4523Japan$9.14B10,5436.7%33.3
CiplaCIPLAIndia$11.93B31,36913.0%38.8
Zhejiang NHU002001China$12.3B11,50833.8%10.9
Sumitomo Pharma4506Japan$5.69B4,980-0.4%19.2
Zydus LifesciencesZYDUSLIFEIndia$12.59B29,98017.2%28.4

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Kyowa Kirin with its competitors